Ekso Bionics (NASDAQ:EKSO) Receives New Coverage from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a report issued on Friday morning. The brokerage issued a hold rating on the stock.

Other equities research analysts have also issued reports about the stock. Lake Street Capital started coverage on shares of Ekso Bionics in a report on Monday, June 24th. They set a buy rating and a $2.50 price target for the company. HC Wainwright lifted their price objective on shares of Ekso Bionics from $9.25 to $10.00 and gave the company a buy rating in a research report on Tuesday, April 30th.

Ekso Bionics Stock Performance

Shares of EKSO opened at $1.04 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.11 and a current ratio of 2.81. The company has a market capitalization of $18.90 million, a price-to-earnings ratio of -1.07 and a beta of 1.51. The company’s 50 day simple moving average is $1.20 and its 200 day simple moving average is $1.60. Ekso Bionics has a 1 year low of $0.62 and a 1 year high of $3.13.

Ekso Bionics (NASDAQ:EKSO) last posted its quarterly earnings results on Monday, April 29th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.04). The company had revenue of $3.76 million for the quarter, compared to analysts’ expectations of $4.99 million. Ekso Bionics had a negative return on equity of 95.36% and a negative net margin of 79.48%. During the same period in the prior year, the business earned ($0.33) EPS. On average, sell-side analysts predict that Ekso Bionics will post -0.43 EPS for the current year.

Hedge Funds Weigh In On Ekso Bionics

An institutional investor recently raised its position in Ekso Bionics stock. Strategic Wealth Investment Group LLC lifted its holdings in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 21.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 51,950 shares of the company’s stock after purchasing an additional 9,285 shares during the period. Strategic Wealth Investment Group LLC owned about 0.37% of Ekso Bionics worth $130,000 at the end of the most recent reporting period. Institutional investors own 6.42% of the company’s stock.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.